<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Participant</th>
<th>Date</th>
<th>Recruitment Target</th>
<th>Recruited?</th>
<th>Sponsor</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>12362019</td>
<td>195062</td>
<td>GW0083-103</td>
<td>10/01/2018</td>
<td>06/11/2017</td>
<td>Neither</td>
<td>Sponsor Delays</td>
<td>06/11/2017</td>
</tr>
<tr>
<td>12362019</td>
<td>195062</td>
<td>GW0083-103</td>
<td>10/01/2018</td>
<td>06/11/2017</td>
<td>Neither</td>
<td>Sponsor Delays</td>
<td>06/11/2017</td>
</tr>
<tr>
<td>12362019</td>
<td>195062</td>
<td>GW0083-103</td>
<td>10/01/2018</td>
<td>06/11/2017</td>
<td>Neither</td>
<td>Sponsor Delays</td>
<td>06/11/2017</td>
</tr>
<tr>
<td>12362019</td>
<td>195062</td>
<td>GW0083-103</td>
<td>10/01/2018</td>
<td>06/11/2017</td>
<td>Neither</td>
<td>Sponsor Delays</td>
<td>06/11/2017</td>
</tr>
</tbody>
</table>

**Notes:**
- GW0083-103: Investigating the safety and tolerability of GW0083-103 in patients with non-valvular atrial fibrillation.
- Sponsor Delays: The sponsor experienced delays in providing essential information to pharmacy.
- Recruitment Target: The recruitment target was not met due to a delay in study site enrollment.
- Recruited?: The site declined to participate in the study.
- Comments: The sponsor did not provide HRA approval letter to site until 19th December 2017. Contracting delays - sponsor delayed/denied contract.

---

**Clinical Trials:**
- **Study to Assess the Safety and Efficacy of Filgotinib, GS-4059 in Adult Subjects with Active Sjogren's Syndrome:**
  - Recruitment: 02/11/2017
  - Recruited: 08/11/2017
  - Comments: The site declined to participate in the study due to some clinical reasons that the site felt they would be able to deliver clinical studies.
- **Randomized Controlled Trial of Cryo Ablation versus Alternative to Parenteral Nutrition for Patients with Major Trauma Hemorrhage:**
  - Recruitment: 02/11/2017
  - Recruited: 08/11/2017
  - Comments: The sponsor did not provide HRA approval letter to site until 19th December 2017. Contracting delays - sponsor delayed/denied contract.
- **A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS-2820 in Patients with Inflammatory Bowel Disease:**
  - Recruitment: 02/11/2017
  - Recruited: 08/11/2017
  - Comments: The site declined to participate in the study due to some clinical reasons that the site felt they would be able to deliver clinical studies.
- **A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eribulin Mesylate in Participants with Progressive Supranuclear Palsy:**
  - Recruitment: 02/11/2017
  - Recruited: 08/11/2017
  - Comments: The site declined to participate in the study due to some clinical reasons that the site felt they would be able to deliver clinical studies.
- **A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GS-3120 in Patients with Non-Valvular Atrial Fibrillation:**
  - Recruitment: 02/11/2017
  - Recruited: 08/11/2017
  - Comments: The site declined to participate in the study due to some clinical reasons that the site felt they would be able to deliver clinical studies.

---

**Research Ethics Committee Numbers:**
- 17/EM/0371
- 14/SW/1061
- 17/LO/2058
- 15/NS/0113
- 17/LO/1245
- 17/EE/0382
- 17/EE/0429
- 17/EE/0431

---

**Study Names:**
- **Randomized Controlled Trial of Cryo Ablation versus Alternative to Parenteral Nutrition for Patients with Major Trauma Hemorrhage:**
- **Study to Assess the Safety and Efficacy of Filgotinib, GS-4059 in Adult Subjects with Active Sjogren's Syndrome:**
- **Randomized Controlled Trial of Cryo Ablation versus Alternative to Parenteral Nutrition for Patients with Major Trauma Hemorrhage:**
- **A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS-2820 in Patients with Inflammatory Bowel Disease:**
- **A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eribulin Mesylate in Participants with Progressive Supranuclear Palsy:**
- **A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GS-3120 in Patients with Non-Valvular Atrial Fibrillation:**

---

**Contact Information:**
- **Research Ethics Office:**
  - Phone: 01234 567890
  - Email: research@ethics.org
  - Address: 123 Research Street, City, Country
<table>
<thead>
<tr>
<th>Date</th>
<th>Code</th>
<th>Trial Name</th>
<th>Outcome</th>
<th>Reason</th>
<th>Sponsor/Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>26/05/2018</td>
<td>211995</td>
<td>The study aims to evaluate the safety and efficacy of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>195538</td>
<td>Clinical Trial Evaluation of the Performance of Michelson's Karman Non-Destructible Repair System</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>231977</td>
<td>Female Subject: Trial of a 50 ml/70 ml prophylactic device to be inserted into the arm of women who are at risk of venous thromboembolism. No patients seen</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/11/2018</td>
<td>220783</td>
<td>A patient was found to be unfit for recruitment. The patient was referred to their GP for further investigation.</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>11/04/2018</td>
<td>220362</td>
<td>Planned to screen 5 patients for the study. Site is currently performing 100% follow-up.</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>11/04/2018</td>
<td>220392</td>
<td>Planned to screen 5 patients for the study. Site is currently performing 100% follow-up.</td>
<td>Yes</td>
<td>Sponsor/Other</td>
<td></td>
</tr>
<tr>
<td>16/05/2018</td>
<td>295623</td>
<td>A randomized study of a first time intervention for primary prevention of vascular disease in patients with high blood pressure and poor medication adherence (BRATCITY)</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>290739</td>
<td>A multicentre, non-inferiority, parallel group, double-blind, placebo-controlled study to assess the efficacy and safety of the investigational drug in patients with chronic obstructive pulmonary disease (COPD).</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>290769</td>
<td>The study is ongoing and the site has been approved for recruitment.</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>290993</td>
<td>A phase 3, open-label, multicentre, international, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>17/06/2018</td>
<td>280629</td>
<td>A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>13/07/2018</td>
<td>210693</td>
<td>A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>12/07/2018</td>
<td>210793</td>
<td>A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>13/07/2018</td>
<td>210880</td>
<td>A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
<tr>
<td>12/07/2018</td>
<td>204862</td>
<td>A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with...</td>
<td>No</td>
<td>1/Other</td>
<td>Sponsor/Other</td>
</tr>
</tbody>
</table>

**Trial Titles:**
- SCLEROSIS TO EVALUATE THE EFFICACY AND SAFETY OF BIIB033 AS AN ADD-ON THERAPY TO ANTI-INFLAMMATORY DISEASE-MODIFYING THERAPIES IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS TO EVALUATE THE Efficacy AND SAFETY OF BIIB033 AS AN ADD-ON THERAPY TO ANTI-INFLAMMATORY DISEASE-MODIFYING THERAPIES IN SUBJECTS WITH RELAPSING MULTIPLE SCLEROSIS. No patients seen. No patients enrolled.
- A multicentre international randomized parallel group, double-blind, placebo-controlled study to assess the efficacy and safety of the investigational drug in patients with chronic obstructive pulmonary disease (COPD). No patients seen. No patients enrolled.
- A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with... No patients seen. No patients enrolled.
- A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with... No patients seen. No patients enrolled.
- A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with... No patients seen. No patients enrolled.
- A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with... No patients seen. No patients enrolled.
- A phase 2, open-label, randomised, controlled study to evaluate the efficacy and safety of the investigational drug in patients with... No patients seen. No patients enrolled.